Regenerative medicine firm soars above IPO price on KOSDAQ debut

By Ryu Yuna Posted : October 22, 2026, 17:32 Updated : October 22, 2026, 17:32
Courtesy of MS Bio
SEOUL, October 22 (AJP) - Regenerative medicine firm MS Bio more than doubled from its initial public offering (IPO) price on its KOSDAQ debut Thursday before paring gains later in the day.

The stock climbed as high as 19,650 won (US$14.81), about 2.5 times its IPO price of 7,800 won. It was trading at 12,920 won as of around 5 p.m. in after-hours trading, up 65.64 percent from the offering price.

The firm priced its shares at the top of its proposed range of 6,800 won to 7,800 won after institutional investors submitted bids exceeding the shares available by 1,096.56 times. The IPO drew 2,269 institutional investors during the book-building process.

Retail demand was also strong, with subscriptions oversubscribed 1,538.51 times and investors placing approximately 6.02 trillion won in deposits for share allocations. KB Securities served as the lead underwriter for the 31.2 billion won offering.

Founded in 2015, MS Bio develops and manufactures medical products using donated human tissue and biomaterials to help repair and regenerate damaged skin, bone and other tissues.

It posted revenue of 23.79 billion won and operating profit of 8.56 billion won in 2025.

The firm plans to use proceeds from its IPO to build a new manufacturing facility in Ochang, North Chungcheong Province, increase production capacity and expand into overseas markets including Viet Nam and the U.S.

Copyright ⓒ Aju Press All rights reserved.